The shares of Glenmark Pharmaceuticals Ltd were trading in the green and 1% higher on 17 May after the company announced receiving final approval from the USFDA. 

The generic brimonidine tartrate and timolol maleate ophthalmic solution from Glenmark Pharmaceuticals Ltd. has received final approval from the US Food and Drug Administration (USFDA). 

Brimonidine tartrate and timolol maleate ophthalmic solution is used by people with glaucoma or other conditions to relieve increased intraocular pressure (HIP).

In a statement from Glenmark, the US Food & Drug Administration announced that the brimonidine tartrate and timolol maleate ophthalmic solution of strength 0.2%/0.5% had gained final approval.

The USFDA came to the conclusion that the company’s 0.2%/0.5% brimonidine tartrate and timolol maleate ophthalmic solution was therapeutically and bioequivalent to AbbVie, Inc.’s 0.2%/0.5% Combigan ophthalmic solution.

It further said that the medicine would be distributed in the US by Glenmark Pharmaceuticals Inc., USA.

Using IQVIATM sales data, the company reported that Combigan ophthalmic solution, 0.2%/0.5%, produced annual sales of about USD 290 million for the 12-month period ending in March 2024.

At 11:32 am, the shares of Glenmark Pharmaceuticals were trading 1.16% higher at Rs 1,017 on NSE.